Avedro is a commercial stage company in the refractive vision correction market. The company has developed the KXL System, an accelerated corneal crosslinking device for treatment of keratoconus and post-LASIK ectasia; and the Vedera System, a non-surgical procedure for refractive vision correction.

DIR applies electro-optic infrared technology in a variety of non-contact pharmacological tests, such as the identification of counterfeit drugs through the original package, and rigorous quality assurance techniques for the fabrication process of world leading pharmaceutical industries.

EndoSpan is developing the next generation in EndoVascular Aortic Aneurysm Repair (EVAR) devices. EndoSpan`s system aims to achieve a much smaller crossing profile compared with contemporary devices, while requiring only one-sided intervention thus simplifying and significantly shortening the procedure.

Garnet BioTherapeutics is a cell therapy company focused on dermal-based regenerative therapy. The company has developed proprietary scalable cell-manufacturing technology that has largely solved the challenges of commercial manufacturing scale-up of patient doses from a single donor source.

Ivenix (formerly FluidNet) is developing advanced smart IV infusion system solutions. The device's unique engineering will address the evolving workflow, connectivity, safety, and regulatory demands; improve and simplify the user experience; and improve clinical outcomes.

LZ Therapeutics is a biopharmaceutical company developing novel therapeutics for neurological diseases, initially targeting Parkinson's disease. The Company’s goal is to develop therapeutics, which would improve patient outcomes, including improved symptom control and potential disease modification.

MST is developing an Image Guided Laparoscope Manipulator for the laparoscopic market. MST’s product automatically navigates and focuses the laparoscope, enabling fluid surgical workflow, and streamlining the coordination between a surgeon and a camera-manipulating assistant.

novoGI is commercializing a family of CE-marked and FDA-cleared surgical devices for the gastro-intestinal surgery market. The Company’s Nitinol-based products enable natural anastomotic tissue closure by pressing together the ends of resected tissue, with no foreign body reaction.

Pocared has developed an innovative clinical in-vitro diagnostic system that provides real-time detection and identification of pathogens. The system is highly automated, provides quick test turnaround, and does not require the use of reagents; providing laboratories with a compelling economic value proposition.

Recro Pharma (NASDAQ:REPH) is a specialty biopharmaceutical company developing differentiated, high value, prescription drugs for analgesia, anesthesia, sedation and other specialty markets. Recro is currently focusing on proprietary drug solutions for chronic pain, breakthrough pain, and acute post-operative pain.

Regentis Biomaterials is developing innovative biodegradable hydrogels for the local repair of damaged cartilage and bone. The Company’s Gelrin™ family of hydrogels incorporates denatured fibrinogen as a crosslinking agent, which produces a unique biodegradation profile in-vivo.

ReWalk Robotics (NASDAQ:RWLK) is a commercial stage company that has developed the ReWalk™, an exoskeleton for people suffering from lower-limb disabilities. ReWalk™ is a user-initiated wearable brace support suit, that enables paralyzed people to stand, walk and climb stairs.

Sensible Medical Innovations is developing a non-invasive device for monitoring congestive heart failure. The system continuously measures various parameters that estimate pulmonary congestion, which is a precursor to cardiac congestion. This can alert patients to a deterioration in their condition.

Spine21 is developing a technology platform for the orthopedics market, enabling non-invasive post-operative adjustment of long-term implants. The company's first product is a minimally invasive, motion-preserving, interspinous spacer to treat low back and leg pain.